2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid

We are 2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid CAS:2766-17-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid
CAS.NO: 2766-17-8
Molecular Formula:C17H24N2O5
Molecular Weight:336.38300

Synonyms:
Nα-(benzyloxycarbonyl)-L-valyl-glycine ethyl ester
Z-Val-Gly-OC2H5
Cbz-valylglycine ethyl ester
ethyl ester of N-benzyloxycarbonyl-L-valylglycine
ethyl [(2S)-2-(benzyloxycarbonylamino)-3-methylbutanoylamino]acetate
ethyl N-(benzyloxycarbonyl)-L-valylglycinate
Z-VAL-GLY-OET

Physical and Chemical Properties:
Density: 1.146±0.06 g/cm3(Predicted)
Boiling point: 516.4±40.0 °C(Predicted)
Melting point: 105 °C
Flash point: /
Refractive index: 1.538

Specification:
Appearance: White Crystalline Powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -15ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]acetic acid


Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.1000339-51-4 In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.10-yodo-1-decanol CAS:57395-49-0 In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.145238-17-1 In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.

Related Products
Product Name
4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine View Details
2-Chloro-3,5-dinitrobenzotrifluoride View Details
Diphenyldiethoxysilane View Details
N-(3-nitrophenyl)-3-oxobutanamide manufacturer p-Tolunitrile manufacturer 2,3-Difluoro-6-methylpyridine manufacturer 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide manufacturer Ethyl 7-hydroxy-7-phenylheptanoate manufacturer